GLG News by Dermatolopathologists (US)

The recent results for a trial of Relieva in atopic dermatitis or eczema, a cream containing a homeopathic compound, were positive by a report from the company. The study sample was small, and the trial was open label. Generally these trials have a larger number of patients, and are blinded. Also it...

 The FDA warning to Melanocorp regarding their product Melanotan was justified. These warnings are far too few and infrequent, and numerous companies make claims without studies or substantiation. The agency is overwhelmed with NDA's, and has difficulty handling the work that currently exists....

I do not believe that Vaniqa will have a negative effect on Laser hair removal as its efficacy is only temporary. In fact we use it as an adjunct for patients with resistant areas. Its use may actually enhance the use of Laser devices as they offer permanence. The products use may be increasing as more...

Advitech's launch of Dermylex will not have much of an impact on the psoriasis market. This is due to the fact that the product has minimal studies to back it up, and the company will rely on testimonials. This is not an effective way of marketing to physicians, and is difficult with patients....

If Melafinds phase three study results are positive then physicians will in general be receptive. The only issues are: 1. Ease of use/time to scan 2. Ability for non physician personnel to be trained to use the technology. 3. cost 4. Insurance reimbursement The technology may have more use at larger...

The new Modus product "without hydroquinone" cannot be fully evaluated on the basis of the currently available information. Decisions based on the opinions of a "Beauty Editor", and 6 years worth of studies with only 4 patients, are tenuous at best, and laughable at worst. It will be difficult to unseat...

The possible ban of over the counter hydroquinone skin bleaching agents may be premature. We have used these agents for 20 years without any significant side effects including ochronosis or paradoxical darkening of the skin. These agents are only modestly effective at best. Most patients still...

The recent Epiceram phase 4 data comparing it to Cutivate are positive, and bode well for the product. The concept of barrier repair makes sense in light of the recent findings in regards to the genetic basis of atopic dermatitis. Repairing the barrier with Epiceram will reduce inflammation, and the...

Altabax (retapamulin) will be a competitive topical agent for impetigo because it is a new molecular entity, Bactroban or mupirocin is generic and cannot compete directly, and it is indicated for children as young as 9 months. The market for a nonoral antibiotic is always good, due to lower side ef...

ELEVESS received its CE mark approval in Europe. The product is entering a crowded field with no real differentiating factors other than having lidocaine as an anesthetic. To release this product in the US without a partnership with an established company will be very hard. It will not be easy to compete...